WO2012103324A2 - Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto - Google Patents

Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto Download PDF

Info

Publication number
WO2012103324A2
WO2012103324A2 PCT/US2012/022706 US2012022706W WO2012103324A2 WO 2012103324 A2 WO2012103324 A2 WO 2012103324A2 US 2012022706 W US2012022706 W US 2012022706W WO 2012103324 A2 WO2012103324 A2 WO 2012103324A2
Authority
WO
WIPO (PCT)
Prior art keywords
igg
iga
igm
brain barrier
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/022706
Other languages
English (en)
French (fr)
Other versions
WO2012103324A3 (en
Inventor
Aristo Vojdani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunosciences Lab Inc
Original Assignee
Immunosciences Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2013139476A priority Critical patent/RU2607479C2/ru
Priority to HK14102850.9A priority patent/HK1189938B/xx
Priority to AU2012211328A priority patent/AU2012211328A1/en
Priority to KR1020137022644A priority patent/KR101941308B1/ko
Priority to CN201280015809.0A priority patent/CN103460044B/zh
Priority to NZ614707A priority patent/NZ614707B2/en
Priority to BR112013019380A priority patent/BR112013019380A2/pt
Priority to MX2013008746A priority patent/MX2013008746A/es
Priority to JP2013551330A priority patent/JP6068362B2/ja
Priority to CA2828194A priority patent/CA2828194A1/en
Application filed by Immunosciences Lab Inc filed Critical Immunosciences Lab Inc
Priority to EP12739704.0A priority patent/EP2668498B1/en
Publication of WO2012103324A2 publication Critical patent/WO2012103324A2/en
Publication of WO2012103324A3 publication Critical patent/WO2012103324A3/en
Priority to IL227676A priority patent/IL227676A/en
Anticipated expiration legal-status Critical
Priority to AU2016259430A priority patent/AU2016259430B2/en
Priority to AU2016262726A priority patent/AU2016262726B2/en
Priority to IL250871A priority patent/IL250871B/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/709—Toxin induced

Definitions

  • the native gut-related antigen is preferably selected from the list consisting of: (1) an intestinal structural protein; (2) a tight junction protein; (3) a binding receptor to the tight junction protein; and (4) a cell junction protein.
  • testing occurs for antibodies to one or more of actin/actomyosin, occludin and/or zonulin, intestinal ZOT receptor, and matrix metalloproteinase-3 (MMP-3).
  • Figure 9 is a diagram showing a comparison of IgG, IgM and IgA against bacterial lipopolysaccharide and occludin/zonulin in healthy donors and patients with gastric autoimmunity.
  • the emphasis of the methodology of the present invention is on large molecules that are antigenic and which, upon their release from the barriers, have the capacity to challenge the immune system, resulting in the production of specific IgG, IgM and/or IgA antibodies against them, which are detected in blood, blood serum, and/or saliva samples.
  • the analytical procedure for IgG, IgM, and/or IgA antibody against LPS, intestinal and/or BBB proteins is now discussed.
  • all reagents were allowed to reach room temperature before the test assay was commenced.
  • the test assay procedure includes preparing the desired number of coated wells or plates with the desired number and type of antigens and/or peptides. Once the microtiter wells are prepared, about 100 ⁇ of 1 : 100 diluted control calibrator are added to Rows A and B of the microtiter plate as shown in Figure 7, which can be done using a multi-channel pipettor.
  • the plates were then incubated for about 60 minutes at room temperature. After incubation, the wells were then emptied and washed four times with PBS using an ELISA Washer. About 100 ⁇ of optimally diluted alkaline phosphatase-labeled goat anti-human IgA was added to the IgA plate or about 100 ⁇ of enzyme-labeled IgG was added to the IgG plate and anti-IgM was added to the IgM plate at optimal dilution.
  • Neurological examination revealed reduced corrected visual acuity of 6/48 in the right eye and 6/36 in the left eye with normal eye movements.
  • the patient had pyramidal weakness in both legs with mildly-based gait.
  • Pinprick examination demonstrated hemisensory level below D10 on both sides.
  • Vojdani A Vojdani E
  • Cooper EL Antibodies to myelin basic protein, myelin oligodendrocytes peptides, ⁇ - ⁇ -crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Internal Med, 2003; 254: 363-74.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2012/022706 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto Ceased WO2012103324A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
HK14102850.9A HK1189938B (en) 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
AU2012211328A AU2012211328A1 (en) 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
KR1020137022644A KR101941308B1 (ko) 2011-01-28 2012-01-26 장, 혈액-뇌 장벽 투과성 검출 방법 및 테스트 물질
CN201280015809.0A CN103460044B (zh) 2011-01-28 2012-01-26 用于检测肠和血脑屏障通透性的方法及其测试材料
NZ614707A NZ614707B2 (en) 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
BR112013019380A BR112013019380A2 (pt) 2011-01-28 2012-01-26 método para detecção de permeabilidade da barreira hematoencefálica, e intestinal e materiais de teste da mesma
MX2013008746A MX2013008746A (es) 2011-01-28 2012-01-26 Metodo para la deteccion de permeabilidad intestinal y de la barrera hemato-encefalica y materiales de prueba para este.
CA2828194A CA2828194A1 (en) 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
JP2013551330A JP6068362B2 (ja) 2011-01-28 2012-01-26 腸および血液脳関門の透過性を検出する方法、およびその試験材料
RU2013139476A RU2607479C2 (ru) 2011-01-28 2012-01-26 Способ обнаружения проницаемости кишечного, а также гематоэнцефалического барьера и материалы для соответствующих тестов
EP12739704.0A EP2668498B1 (en) 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
IL227676A IL227676A (en) 2011-01-28 2013-07-28 A method for detecting permeability through the intestine and through a blood-brain barrier and substances for testing
AU2016259430A AU2016259430B2 (en) 2011-01-28 2016-11-18 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
AU2016262726A AU2016262726B2 (en) 2011-01-28 2016-11-24 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
IL250871A IL250871B (en) 2011-01-28 2017-03-01 A method for detecting permeability through the intestine and through the blood-brain barrier and testing substances from them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437244P 2011-01-28 2011-01-28
US61/437,244 2011-01-28

Publications (2)

Publication Number Publication Date
WO2012103324A2 true WO2012103324A2 (en) 2012-08-02
WO2012103324A3 WO2012103324A3 (en) 2012-11-01

Family

ID=46577669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022706 Ceased WO2012103324A2 (en) 2011-01-28 2012-01-26 Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto

Country Status (12)

Country Link
US (2) US8663911B2 (enExample)
EP (1) EP2668498B1 (enExample)
JP (1) JP6068362B2 (enExample)
KR (1) KR101941308B1 (enExample)
CN (2) CN105823887B (enExample)
AU (3) AU2012211328A1 (enExample)
BR (1) BR112013019380A2 (enExample)
CA (2) CA2964555C (enExample)
IL (2) IL227676A (enExample)
MX (1) MX2013008746A (enExample)
RU (2) RU2016149216A (enExample)
WO (1) WO2012103324A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2628013B1 (en) 2010-10-14 2019-06-12 The Johns Hopkins University Biomarkers of brain injury
US9709573B2 (en) 2012-03-13 2017-07-18 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20140147856A1 (en) * 2012-11-29 2014-05-29 Rush University Medical Center Intestinal Permeability Assay for Neurodegenerative Diseases
WO2015009907A1 (en) 2013-07-17 2015-01-22 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
CN107533048A (zh) 2015-02-05 2018-01-02 美国免疫阵列公司 用于诊断脑损伤或神经退行性变的方法和组合物
US11131676B2 (en) 2016-02-25 2021-09-28 The Trustees Of Columbia University In The City Of New York Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
CN105974105A (zh) * 2016-05-16 2016-09-28 河北艾驰生物科技有限公司 基质金属蛋白酶-3（mmp3）检测试剂盒
JP6782886B2 (ja) 2017-01-19 2020-11-11 国立大学法人島根大学 腸粘膜の透過性の診断薬、診断方法、診断装置
CN108191977B (zh) * 2017-12-25 2018-12-18 首都医科大学宣武医院 用于检测缺血性脑卒中血脑屏障早期损伤的抗体及其应用
CN108152492B (zh) * 2017-12-25 2019-03-08 首都医科大学宣武医院 用于检测缺血性脑卒中血脑屏障早期损伤的抗体及其应用
US12262983B2 (en) 2018-02-07 2025-04-01 University Of Cincinnati System and method for detecting small blood-tissue barrier disruption
KR102341906B1 (ko) * 2018-10-26 2021-12-22 가천대학교 산학협력단 청년기 우울증 동물모델의 제조방법
CN112958172B (zh) * 2021-02-24 2021-12-28 北京航空航天大学 一种模拟体内微生物-肠-脑轴信号传导过程的仿生微流控芯片

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028215A1 (en) * 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
DE19842609C2 (de) * 1998-09-17 2000-09-21 Diagnostik Gmbh Leipzig Lab Salmonellenantigengemisch und Kit zur Bestimmung von Antikörpern gegen Salmonellen
US6958324B2 (en) * 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US6884591B2 (en) * 2001-06-25 2005-04-26 The Cleveland Clinic Foundation Peripheral marker of blood brain barrier permeability
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
US20080038843A1 (en) * 2006-08-11 2008-02-14 University Of Maryland - Baltimore Method of diagnosing celiac disease
CA2651366A1 (en) * 2005-05-13 2006-11-23 Alessio Fasano Method for assessing the effectiveness of a treatment regimen
US7795314B2 (en) * 2005-06-01 2010-09-14 Cytokine Pharmasciences, Inc. Protective role of semapimod in necrotizing enterocolitis
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
JP4791866B2 (ja) * 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
US7892763B2 (en) * 2009-01-26 2011-02-22 Dodds W Jean Multi-stage nutrigenomic diagnostic food sensitivity testing in animals

Non-Patent Citations (64)

* Cited by examiner, † Cited by third party
Title
ALOISI F; RIA F; ADORINI L: "Regulation of T-cell responses by CNS antigen presenting cells: different roles for microglia and astrocytes", IMMUNOL TODAY, vol. 21, no. 3, 2000, pages 141 - 147, XP004202529, DOI: doi:10.1016/S0167-5699(99)01512-1
AL-SADI R; YE D, DOKLADNY K; MA TY: "Mechanism of II,-1 (3-induced increase in intestinal epithelial tight junction permeability", J IMMUNOL, vol. 180, 2008, pages 5653 - 5661
AL-SADI RM; MA TY: "IL-ip causes an increase in intestinal epithelial tight junction permeability", J IMMUNOL., vol. 178, 2007, pages 4641 - 4649
ARRIETA MC; BISTRITZ L; MEDDINGS JB: "Alterations in intestinal permeability", GUT, vol. 55, 2006, pages 1512 - 1520
BALKOVETZ DF; KATZ J: "Bacterial invasion ofparacellular route: divide and conquer", MICROBES INFECT, vol. 5, 2003, pages 613 - 619
BIERNACKI K; PRAT A; BLAIN M; ANTEL JP: "Regulation of Thl and Th2 lymphocyte migration by human adult brain endothelial cells", JNEUROPATHOL EXP NEURAL, vol. 60, no. 12, 2001, pages 1127 - 1136
BLIXT ET AL., GLYCOCONJ J, vol. 25, 2008, pages 27 - 36
CHEN ML ET AL.: "Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells", CAMPYLOBACTER JEJUNI. INFECT IMMUN, vol. 74, 2006, pages 6581 - 6589
CHEVRIER MR; RYAN AE; LEE DY-W ET AL.: "Boswellia carterii extract inhibits the cytokines and promotes Th2 cytokines in vitro", CLIN DIAG LAB IMMUNOL, 2005, pages 575 - 580
CORREALE J; VILLA A: "The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting", AUTOIMMUNITY., vol. 40, 2007, pages 148 - 160, XP008089460, DOI: doi:10.1080/08916930601183522
CYWES C.; WESSELS M.R: "Group A Streptococcus tissue invasion by CD44-mediated cell signaling", NATURE, vol. 414, 2001, pages 648 - 652
EL ASMAR; PANIGRAHI P; BAMFORD P ET AL.: "Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure", GASTROENTEROL, vol. 123, 2002, pages 1607 - 1615
ENGELHARDT B; RASOHOFF RM: "The ins and outs of the T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms", TRENDS IMMUNOL, vol. 26, no. 9, 2005, pages 485 - 495, XP005027888, DOI: doi:10.1016/j.it.2005.07.004
FASANO A: "Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity and cancer", PHYSIOL REV, vol. 91, 2011, pages 151 - 175, XP055421173, DOI: doi:10.1152/physrev.00003.2008
FASANO A; SHEA-DONOHUE T: "Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases", NAT CLIN PRAC GASTROENTEROL HEPATOL., vol. 2, no. 9, 2005, pages 416 - 422
GANOR Y; TEICHBERG VI; LEVITE M: "TCR activation eliminate glutamate receptor GLUR3 from the cell surface of normal human T cells via an autocrine/paracrine granzyme B-mediated proteolytic cleavage", J IMMUNOL, vol. 178, 2007, pages 683 - 692
GARATE I; GARCIA-BUENO B; MADRIGAL, JLM ET AL.: "Origin and consequences of brain toll-like receptor 4 pathway stimulation in an experimental model of depression", J NEUROINFLAMM., vol. 8, 31 January 2011 (2011-01-31), pages 151
GARROTE J; GOMEZ-GONZALEZ E; BERNARDO D; ARRANZ E; CHIRDO F: "Celiac disease pathogenesis: the proinflammatory cytokine network", JPEDIATR GASTROENTEROL NUTR, vol. 47, no. 1, 2008
GHIRNIKAR RS; LEE YL; ENG LF: "Inflammation in traumatic brain injury: role of cytokines and chemokines", NEUROCHEM RES, vol. 23, no. 3, 1998, pages 329 - 340, XP019289397
HAN S; JEONG SY; NAM YJ ET AL.: "Xylitol inhibits inflammatory cytokine expression induced by lipopolysaccharides from Porphyromonas gingivalis", CLIN DIAG LAB IMMUNOL, vol. 12, no. 11, 2005, pages 1285 - 1291, XP055241517, DOI: doi:10.1128/CDLI.12.11.1285-1291.2005
HAWKINS BT; DAVIS TP: "The blood-brain barrier/neurovascular unit in health and disease", PHARMACOL REV, vol. 57, 2005, pages 173 - 185, XP002563573, DOI: doi:10.1124/pr.57.2.4
HECHT G; PESTIC L; NIKCEVIC G; KOUTSOURIS A; TRIPURANENI J; LORIMER DD; NOWAK G; GUERRIERO, JR V; ELSON EL; LANEROLLE PD: "Expression of the catalytic domain of myosin light chain kinase increases paracellular permeabilit", AM J PHYSIOL, vol. 271, 1996, pages C1678 - 1684
HUANG XN; FUJ; WANG WZ: "The effects of Fasudil on the permeability of the rat blood-brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis", J NEUROIMMUNOL., vol. 239, 2011, pages 61 - 67, XP028328735, DOI: doi:10.1016/j.jneuroim.2011.08.015
JUVONEN P; JAKOBSSON I; LINDBERG T: "Macromolecular absorption and cow's milk allergy", ARCH DIS CHILD, vol. 65, 1990, pages 300 - 303
KAWANOKUCHI J; SHIMIZU K; NITTA A; YAMADA K; MIZUNO T; TAKEUCHI H; SUZUMURA A: "Production and function of IL-17 in microglia", J NEUROIMMUNOL, vol. 194, 2008, pages 54 - 61
KEBIR H; KREYMBORG K; IFERGAN I; DODELET-DEVILLERS A; CAYROL R; BERNARD M; BIULIANI F; ARBOUR N; BECHER B; PRAT A: "Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation", NAT MED, vol. 13, 2007, pages 1173 - 1176
KIRK J; PLUMB J; MIRAKHUR M ET AL.: "Tight junctional abnormality in multiple sclerosis white matter affects all calibers of vessel and is associated with blood-brain barrier leakage and active demyelination", J PATHOL., vol. 201, 2003, pages 319 - 327
KUULA H ET AL.: "Local systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis", INFECT IMMUN, vol. 77, no. 2, 2009, pages 850 - 859
LAPIERRE LA: "The molecular structure of the tight junction", ADV DRUG DELIV, vol. 41, 2000, pages 255 - 264
LASSMANN H; ZIMPRICH F; VASS K; HICKEY WF: "Microglial cells are a component of the perivascular glia limitans", J NEUROSCI RES, vol. 28, 1991, pages 236 - 243
LEECH S; KIRK J; PLUMB J ET AL.: "Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis", NEUROPATHOL APPL NEUROBIOL, vol. 33, 2007, pages 86 - 98
MA TY; BOIVIN MA; YE E; PEDRAM A; SAID HM: "Mechanism of TNF-a modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression", AM J PHYSIOL, vol. 288, 2005, pages G422 - G430
MA TY; HOA NT; TRAN DD; BUI V; PEDRAM A; MILLS S; MERRYFIELD M: "Cytochalasin B modulation of Caco-2 tight junction barrier: role of myosin light chain kinase", AM J PHYSIOL, vol. 279, 2000, pages G875 - G885, XP008007887
MA TY; TRAN D; HOA N; NGUYEN D; MERRYFIELD M; TARNAWSKI A: "Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement", MICROSC RES TECH, vol. 51, 2000, pages 156 - 168, XP008007669, DOI: doi:10.1002/1097-0029(20001015)51:2<156::AID-JEMT7>3.0.CO;2-J
MAE M; COUCKE F; ATEGIS JC: "Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome", NEURO ENDOCRINOL LETT, vol. 28, no. 6, 2007, pages 101 - 116
MAE M; KUDERA M; LEUNIS JC: "The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative bacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression", EURO ENDOCRINOL LETT, vol. 29, 2008, pages 117 - 124, XP055114883
MALDONADO GALDEANO C; PERDIGON G: "The probiotic bacillum Lactobacillus casei induces activation of the mucosal immune system through innate immunity", CLIN VACCINE IMMUNOL, vol. 13, no. 2, 2006, pages 219 - 226
MATYSIAK-BUDNIK T; THOMAS-COLLIGNON A; MEGRAUD F; HEYMAN M.: "Alterations of epithelial permeability by Helicobacter and IL-1 beta in vitro: protective effect of rebamipide", DIG DIS SCI,, vol. 46, 2001, pages 1558 - 1566
MORGAN L; SHAH B; RIVERS LE ET AL.: "Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosis", NEUROSCI, vol. 147, 2007, pages 664 - 673, XP022134963, DOI: doi:10.1016/j.neuroscience.2007.04.051
NNALUE ET AL., MICROBIOLOGY, vol. 143, 1997, pages 653 - 662
PERSIDSKY Y; RAMIREZ SH; HAORAH J ET AL.: "Bllod-brain barrier: structural components and function under physiologic and pathologic conditions", JNEUROIMMUNE PHARMACOL, vol. 1, 2006, pages 223 - 236, XP019413836, DOI: doi:10.1007/s11481-006-9025-3
REIJERKERK A; KOOIJ G, VAN DER POL SM ET AL.: "Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier", J IMMUNOL, vol. 181, 2008, pages 3567 - 3574
SAPONE A; LAMMERS KM; CASOLARO V ET AL.: "Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity", BMC MED., vol. 9, 2011, pages 23, XP021098635, DOI: doi:10.1186/1741-7015-9-23
SAPONE A; LAMMERS KM; MAZZARELLA G ET AL.: "Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy celiac disease", INT ARCH ALLERGY IMMUNOL., vol. 152, 2010, pages 75 - 80
SCHNEEBERGER EE; LYNCH RD: "The tight junction: a multifunctional complex", AM J PHYSIOL CELL PHYSIOL, vol. 286, 2004, pages C1213 - C1228
See also references of EP2668498A4
SHEN L; BLACK ED; WITKOWSKI ED; LENCER WI; GUERRIERO V; SCHNEEBRGER EE; TURNER JR: "Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure", J CELL SCI, vol. 119, 2006, pages 2095 - 2106
SHOR DB; BARZILAI 0; RAM M ET AL.: "Gluten sensitivity in multiple sclerosis: experimental myth or clinical truth?", ANN NY ACAD SCI, vol. 1173, 2009, pages 343 - 349
SKARDELLY M; ARMBRUSTER FP; MEIXENSBERGER J ET AL.: "Expression of zonulin, c-kit, glial fibrillary acidic protein in human gliomas", TRANSL ONCOL., vol. 2, 2009, pages 117 - 120
SOSPEDRA M; MARTIN R: "Immunology of multiple sclerosis", ANNU REV IMMUNOL, vol. 23, 2005, pages 683 - 747, XP002470436, DOI: doi:10.1146/annurev.immunol.23.021704.115707
SYROVETS T; BUCHELE B; KRAUSS C ET AL.: "Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with I B kinases", J IMMUNOL, vol. 174, 2005, pages 498 - 506, XP002468964
TURNER JR: "Putting the squeeze'' on the tight junction: understanding cytoskeletal regulation", SEMIN CELL DEV BIOL, vol. 11, 2000, pages 301 - 308, XP001100045, DOI: doi:10.1006/scdb.2000.0180
VOJDANI A; LAMBERT J.: "A gut feeling for immune dysregulation and neuroinflammation", THE AUTISM FILE USA, vol. 31, 2009, pages 56 - 64, XP008170612
VOJDANI A; O'BRYAN T; GREEN JA ET AL.: "Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism", NUTR NEUROSCI., vol. 7, no. 3, 2004, pages 151 - 161
VOJDANI A; VOJDANI E; COOPER EL: "Antibodies to myelin basic protein, myelin oligodendrocytes peptides, α-β-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis", J INTERNAL MED, vol. 254, 2003, pages 363 - 74
WAKABAYASHI H; TAKAKURA N; YAMAUCHI K ET AL.: "Modulation of immunity-related gene expression in small intestine of mice by oral administration of lactoferrin", CLIN VACCINE IMMUNOL, vol. 13, no. 2, 2006, pages 239 - 245
WALKER WA; ISSELBACHER KJ: "Uptake and transfer of macromolecules by the intestine", GASTROENTEROL, vol. 67, 1974, pages 531 - 550
WALKER WA; SANDERSON IR: "Epithelial barrier function to antigens", ANN NY ACAD SCI., vol. 664, 1992, pages 10 - 17
WALKER-SMITH JA; FORD RP; PHILLIPS AD: "The spectrum of gastrointestinal allergies to food", ANN ALLERGY, vol. 53, 1984, pages 629 - 636
WONG V; GUMBINER BM: "A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier", J CELL BIOL, vol. 136, no. 2, 1997, pages 399 - 409, XP002095630, DOI: doi:10.1083/jcb.136.2.399
WOSIK K; CAYROL R; DODELET-DEVILLERS A ET AL.: "Angiotension II controls occluding function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis", JNEUROSCI, vol. 27, 2007, pages 9032 - 9042
WOSIK K; CAYROL R; DODELET-DEVILLERS A; BERTHELET F; BERNARD M; MOUMDJIAN R; BOUTHILLIER A; REUDELHUBER TL; PRAT A: "Angiotensin II controls occluding function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis", JNEUROSCI, vol. 27, no. 34, 2007, pages 9032 - 9042
Y XU; Q YU: "E-cadherin negatively regulated CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis", JBIOL CHEM, vol. 278, 2003, pages 8661 - 8668
YACYSHYN B; MEDDINGS J; SADOWSKI D ET AL.: "Multiple sclerosis patients have peripheral blood CD45RO + B cells and increased intestinal permeability", DIG DIS SCI., vol. 41, no. 12, pages 2493 - 2498

Also Published As

Publication number Publication date
IL227676A (en) 2017-03-30
CA2828194A1 (en) 2012-08-02
IL227676A0 (en) 2013-09-30
US8663911B2 (en) 2014-03-04
RU2607479C2 (ru) 2017-01-10
AU2016259430A1 (en) 2016-12-08
KR101941308B1 (ko) 2019-01-22
JP6068362B2 (ja) 2017-01-25
US9194867B2 (en) 2015-11-24
KR20140052941A (ko) 2014-05-07
US20120196299A1 (en) 2012-08-02
CN103460044A (zh) 2013-12-18
JP2014503829A (ja) 2014-02-13
RU2016149216A (ru) 2018-11-02
MX2013008746A (es) 2014-06-23
CA2964555C (en) 2024-05-14
CN103460044B (zh) 2016-04-20
EP2668498B1 (en) 2019-10-02
IL250871B (en) 2021-05-31
CA2964555A1 (en) 2012-08-02
AU2016262726A1 (en) 2016-12-15
CN105823887B (zh) 2018-06-12
AU2016262726B2 (en) 2018-12-06
HK1189938A1 (zh) 2014-06-20
BR112013019380A2 (pt) 2019-10-01
EP2668498A4 (en) 2015-05-20
WO2012103324A3 (en) 2012-11-01
CN105823887A (zh) 2016-08-03
IL250871A0 (en) 2017-04-30
RU2013139476A (ru) 2015-03-10
US20140186855A1 (en) 2014-07-03
AU2012211328A1 (en) 2013-09-19
NZ614707A (en) 2015-04-24
AU2016259430B2 (en) 2019-01-03
EP2668498A2 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
CA2964555C (en) Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
AU2017201908B2 (en) Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
NZ614707B2 (en) Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
HK1189938B (en) Method for detection of intestinal, and blood-brain barrier permeability and testing materials thereto
NZ614464B2 (en) Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280015809.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739704

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013551330

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/008746

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012739704

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2828194

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20137022644

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013139476

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012211328

Country of ref document: AU

Date of ref document: 20120126

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013019380

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 250871

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 112013019380

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130730